The tumor microenvironment is not a passive backdrop but a dynamic ecosystem composed of cancer cells, stromal cells, immune infiltrates, extracellular matrix components, and a plethora of signaling molecules. These constituents engage in a sophisticated web of communication, facilitating adaptive metabolic rewiring that enables tumor cells to survive and proliferate even under harsh conditions such as hypoxia or nutrient scarcity. Metabolic flexibility manifests prominently in altered glucose metabolism, lipid signaling, and amino acid pathways, creating a metabolically hostile microenvironment that paradoxically supports tumor resilience.

Researchers are now leveraging state-of-the-art multi-omics technologies, including genomics, transcriptomics, proteomics, and metabolomics, to decode this complex system. These integrative analyses have revealed that cancer-associated fibroblasts (CAFs), immune cells such as tumor-associated macrophages (TAMs), and endothelial cells undergo distinct metabolic shifts that complement and support cancer cell metabolism. For instance, CAFs often switch to aerobic glycolysis—known as the Warburg effect—to produce lactate, which cancer cells then utilize as a fuel source via oxidative phosphorylation, illustrating a metabolic symbiosis within the tumor niche.

Another pivotal discovery entails the functional crosstalk mediated by metabolic intermediates and secreted factors. Lactate, previously considered a mere waste product, now emerges as a central oncometabolite facilitating immune evasion by promoting regulatory T-cell differentiation and suppressing cytotoxic T lymphocytes. Similarly, tumor-derived exosomes transport metabolic enzymes and microRNAs that reprogram recipient stromal and immune cells, thereby sculpting a microenvironment conducive to tumor progression and metastasis. Such bidirectional communication challenges the paradigm of targeting cancer cells alone, hinting at the necessity of intercepting these metabolic dialogues.

Hypoxia-inducible factors (HIFs) act as master regulators of metabolic adaptation within the TME. In hypoxic niches, HIF-driven transcriptional programs upregulate glycolytic enzymes and angiogenic factors, supporting vascular remodeling and nutrient supply. This adaptation, while aiding tumor survival, also imposes immunosuppressive effects through accumulation of adenosine and modulation of immune checkpoints. The metabolic penalties exacted by hypoxia thus ripple through the TME, altering cellular phenotypes and responses to therapy, offering insights for rational drug development.

The integration of metabolomic profiling has unveiled unique metabolic fingerprints that correlate with tumor aggressiveness and therapy response. Mass spectrometry-based analyses identify differential abundance of key metabolites such as glutamine, serine, and fatty acids, which serve as both diagnostic markers and therapeutic targets. Targeting these metabolic nodes, either through enzyme inhibition or nutrient restriction, demonstrates promising antitumor efficacy in preclinical models, underscoring the translational potential of metabolic interventions.

Importantly, the application of multi-omics data supports the stratification of patients based on their TME metabolic landscape, enabling precision oncology approaches. By mapping tumor-stroma interactions and metabolic fluxes, clinicians can predict resistance mechanisms and tailor combination therapies that simultaneously inhibit cancer cell metabolism and modulate the immune milieu. Such personalized strategies are expected to enhance efficacy while minimizing off-target toxicities, revolutionizing cancer treatment paradigms.

Emerging therapeutics aim to disrupt specific metabolic exchanges within the TME to dismantle the supportive infrastructure sustaining tumors. Inhibitors of monocarboxylate transporters (MCTs), responsible for lactate shuttling between stromal and cancer cells, have shown significant promise. These agents effectively starve cancer cells of critical metabolites and reprogram immune cells to a pro-inflammatory phenotype. Combining such metabolic inhibitors with immune checkpoint blockade holds tremendous potential to synergistically reinvigorate antitumor immunity.

Moreover, lipid metabolism reprogramming within the TME has gained attention for its role in modulating membrane dynamics, signaling cascades, and energy homeostasis. Alterations in fatty acid synthesis and beta-oxidation influence not only cancer cell proliferation but also macrophage polarization towards tumor-promoting phenotypes. Pharmacological targeting of key enzymes such as fatty acid synthase (FASN) and carnitine palmitoyltransferase 1 (CPT1) can reverse these effects, offering new therapeutic windows.

The multi-omics approach further unravels the complexity of amino acid metabolism in the TME. Cancer cells frequently depend on non-essential amino acids like glutamine and serine for nucleotide biosynthesis, redox balance, and epigenetic regulation. Concurrently, immune cells within the TME undergo metabolic constraints due to amino acid depletion, leading to impaired effector functions. Strategies to restore amino acid availability or inhibit cancer cell uptake pathways could rebalance this metabolic tug-of-war, enhancing immunosurveillance.

Epigenetic regulation in response to metabolic shifts also figures prominently in shaping the TME. Metabolites such as alpha-ketoglutarate and succinate function as cofactors or inhibitors of chromatin-modifying enzymes, influencing gene expression and cellular identity. These findings highlight an additional layer whereby metabolism affects tumor biology beyond energy production, providing further targets for intervention.

Beyond the cellular and molecular changes, metabolic reprogramming influences extracellular matrix remodeling and angiogenesis, contributing to tumor invasiveness. Enzymes like matrix metalloproteinases (MMPs) activated by metabolic cues degrade extracellular barriers, facilitating metastasis. Angiogenic switch induced by metabolic stress ensures sustained nutrient delivery but creates aberrant vessels that hinder drug penetration. Therapeutic strategies integrating metabolic modulation with normalization of the tumor vasculature promise improved drug delivery and efficacy.

As this field advances, artificial intelligence and machine learning emerge as indispensable tools for integrating vast multi-omics datasets, uncovering hidden metabolic networks and predictive biomarkers within the TME. Such computational frameworks accelerate hypothesis generation and validation, enabling rapid clinical translation. The convergence of technology and biology heralds a new era of precision oncology, where metabolic vulnerabilities are exploited to outmaneuver even the most recalcitrant tumors.

The study of metabolic reprogramming and functional crosstalk within the tumor microenvironment underscores that cancer is not merely a cellular disease but a systemic metabolic disorder. Holistic, multi-omics approaches provide unprecedented resolution, exposing the intricate dependencies that tumors forge with their surroundings. This knowledge enables the development of innovative combinatorial therapies aimed at metabolic circuits, immune modulation, and microenvironmental remodeling, potentially overcoming longstanding barriers in cancer treatment.

Ultimately, harnessing the insights from metabolic reprogramming within the tumor microenvironment offers hope for durable responses and long-term remission. By targeting the very processes that permit tumors to adapt and evade, this research opens transformative paths toward conquering cancer, promising a future where malignant growths can be controlled and even eradicated through precision metabolic interventions.

Subject of Research: Metabolic reprogramming and functional crosstalk within the tumor microenvironment and a multi-omics anticancer approach

Article Title: Metabolic reprogramming and functional crosstalk within the tumor microenvironment (TME) and A Multi-omics anticancer approach

Article References:
Mir, R., Javid, J., Ullah, M.F. et al. Metabolic reprogramming and functional crosstalk within the tumor microenvironment (TME) and A Multi-omics anticancer approach. Med Oncol 42, 373 (2025). https://doi.org/10.1007/s12032-025-02945-5

Image Credits: AI Generated

HNSCC remains a formidable clinical challenge due to its aggressive nature and limited response to traditional treatments. The metabolic rewiring of cancer cells—particularly the aberrant accumulation and utilization of lactate—has been recognized as a hallmark of various malignancies, influencing tumor progression and immune evasion. Lactate, once considered a mere metabolic byproduct, is now understood to shape the tumor microenvironment (TME) profoundly, orchestrating immune cell behavior and facilitating immune suppression. Despite these insights, the prognostic relevance of lactate metabolism-related genes (LMRGs) in HNSCC and their interplay with immune components remained poorly characterized until now.

The authors embarked on an ambitious effort to construct a robust prognostic model based on the expression patterns of LMRGs. By analyzing extensive patient datasets through integrative genomic and transcriptomic profiling, they developed a multigene signature capable of stratifying patients into discrete risk categories with significantly different overall survival (OS) and progression-free survival (PFS) outcomes. This signature provides clinicians with a powerful tool to identify high-risk patients who may benefit from intensified or tailored therapeutic interventions.

Delving deeper, the study evaluated how this lactate-centric signature correlates with the immune milieu within tumors. The low-risk group, characterized by diminished lactate metabolism, demonstrated notably higher infiltration of CD8+ T cells, potent effectors of anti-tumor immunity. This immunologically "hot" phenotype aligns with a more favorable prognosis and suggests that metabolic modulation could potentiate immune responses. Conversely, tumors in the high-risk category exhibited metabolic profiles conducive to immune suppression, denoting a "cold" microenvironment less amenable to immune clearance.

To unravel cellular heterogeneity within the TME, the researchers employed state-of-the-art single-cell sequencing technologies. This approach revealed remarkable insights: tumor cells displayed the highest lactate metabolic activity among all cell types in the microenvironment, indicating their metabolic dominance and potential contribution to immune suppression. Such granular data emphasize that targeting tumor-specific metabolic pathways holds substantial promise for altering TME dynamics.

Central to the study’s findings is the identification of PYGL, a gene encoding glycogen phosphorylase, liver form, as the most critical prognostic factor within the LMRG signature. Fascinatingly, PYGL was predominantly expressed not only in tumor cells but also in tumor-associated macrophages (TAMs), a key immune subset implicated in cancer progression. The functional role of PYGL in TAMs appears to involve the suppression of M1 macrophage polarization—the phenotype typically associated with inflammatory and tumoricidal functions—thereby skewing the immune microenvironment toward a more tumor-permissive state.

Experimental knockdown of PYGL in vitro yielded compelling evidence of its functional importance: reduced PYGL levels led to decreased lactate production, supporting the gene’s direct involvement in metabolic regulation. Moreover, PYGL expression inversely correlated with CD8+ T cell presence in tumors, reinforcing its role in shaping immune exclusion. These findings illuminate a novel mechanism by which tumor metabolism intersects with immune cell function to influence cancer progression.

Intriguingly, the study also implicated PYGL in copper-dependent cell death pathways, a less explored avenue of cancer biology. This connection suggests that PYGL’s involvement in cell viability extends beyond metabolism, potentially linking to metal-ion homeostasis and programmed cell death mechanisms. The dual role of PYGL may thus represent an Achilles’ heel exploitable for therapeutic gain.

In pursuit of translational impact, the researchers utilized in silico drug screening methods to identify compounds targeting PYGL. Elesclomol, a copper ionophore known for inducing oxidative stress and cell death, emerged as a promising candidate. Treatment with elesclomol demonstrated enhanced efficacy in PYGL-knockdown cells, underscoring the potential for combinatorial strategies that disrupt metabolic and cell death pathways simultaneously.

This comprehensive study advances our understanding of how lactate metabolism influences tumor biology and immune interactions in HNSCC. The prognostic gene signature offers a novel biomarker panel with immediate clinical applicability, guiding personalized medicine efforts. Simultaneously, the elucidation of PYGL’s multifaceted role unlocks new therapeutic avenues, potentially enhancing the efficacy of existing immunotherapies by overcoming metabolic barriers.

Beyond its immediate findings, this research exemplifies the power of integrating multi-omics data and single-cell analyses to decode complex cancer ecosystems. As precision oncology continues to evolve, such integrative approaches will be vital in uncovering hidden vulnerabilities within tumors, tailoring treatments to individual patient profiles, and ultimately improving survival outcomes.

Given the immunosuppressive effects of lactate accumulation within the TME, strategies aiming to inhibit PYGL or modulate lactate pathways could revitalize anti-tumor immunity. This approach aligns with broader efforts to counteract metabolic checkpoints that tumors exploit to escape immune surveillance. By normalizing metabolic imbalances, therapy may shift the TME towards an environment conducive to robust immune activation.

The discovery that PYGL suppression enhances sensitivity to elesclomol also opens the door for repurposing existing drugs or developing novel agents focused on metabolic regulation. Clinical trials designed to test such combinations in HNSCC patients, particularly those identified by the prognostic signature as high-risk, could transform treatment paradigms.

Moreover, the link between PYGL and copper-dependent cell death introduces a fresh perspective on metabolic vulnerabilities. Targeting metal ion homeostasis within tumors could complement immunotherapeutic strategies, fostering an integrated attack on cancer cells. This multifactorial approach underscores the complexity of tumor biology and the necessity for multi-pronged interventions.

In conclusion, the integration of multi-omics data has unearthed critical insights into how lactate metabolism governs immune landscapes and influences the clinical trajectory of HNSCC. PYGL stands out as a linchpin in this network, simultaneously mediating metabolic fluxes, immune modulation, and cell death pathways. These findings herald a new era of targeted therapies designed to disrupt metabolic crosstalk within tumors and enhance immunotherapy effectiveness, promising improved outcomes for patients battling head and neck cancers.

Subject of Research: Head and neck squamous cell carcinoma (HNSCC) lactate metabolism and immune microenvironment.

Article Title: Integrated multi-omics reveal lactate metabolism-related gene signatures and PYGL in predicting HNSCC prognosis and immunotherapy efficacy.

Article References:
Chen, X., Jiang, Z., Pan, J. et al. Integrated multi-omics reveal lactate metabolism-related gene signatures and PYGL in predicting HNSCC prognosis and immunotherapy efficacy. BMC Cancer 25, 773 (2025). https://doi.org/10.1186/s12885-025-13982-8

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-13982-8

To dissect the molecular signatures differentiating healthy liver tissues from those affected by non-viral CLD adjacent to HCC lesions, the team employed RNA sequencing (RNA-seq) alongside metabolomic profiling. RNA-seq technology enables researchers to quantify gene expression by sequencing RNA transcripts comprehensively, thereby illuminating which genes are actively transcribed and their relative abundance. By contrasting transcriptomic data between normal and diseased tissue, the researchers identified differential gene expression patterns indicative of altered biological pathways potentially driving HCC pathogenesis.

Simultaneously, metabolomic analysis provided a complementary dimension, cataloging the small-molecule metabolites present within liver specimens. Metabolites reflect the biochemical activity and metabolic flux within cells, revealing perturbations that may not be evident at the gene expression level alone. By integrating transcriptomic and metabolomic data sets—a technique known as multi-omics—the investigators constructed a holistic molecular landscape characterizing the liver’s shift from health to disease, thereby pinpointing critical dysregulated pathways.

The study revealed two distinct molecular subtypes within the CLD category. Subtype 1 was hallmarked by heightened expression of inflammatory markers, signifying a microenvironment rich in pro-inflammatory signaling cascades. This subtype aligns with previous research highlighting chronic inflammation as a predisposing factor for oncogenic transformation within the liver. Conversely, Subtype 2 corresponded to an older patient cohort and was typified by perturbed lipid metabolism, including diminished fatty acid catabolism and increased fatty acid accumulation, coupled with notable metabolite deficiencies. These findings suggest an age-associated metabolic derangement contributing to hepatic carcinogenesis independent of inflammatory processes.

Of particular interest, both CLD subtypes exhibited suppression of genes associated with fatty acid metabolism, highlighting a fundamental metabolic imbalance in disease states. The fatty acid metabolic disruption observed in Subtype 2, alongside the inflammatory milieu of Subtype 1, illustrate diverse, yet convergent, molecular pathways fostering tumor progression. These insights emphasize the heterogeneity inherent in HCC development and challenge the notion of a one-size-fits-all therapeutic intervention.

Leveraging the knowledge of these molecular aberrations, the research team explored therapeutic modalities capable of mitigating the identified pathway dysregulations. One promising candidate is epigallocatechin gallate (EGCG), a potent antioxidant derived from green tea, previously demonstrated in murine models to attenuate expression of inflammatory pathways induced by high-fat diets mimicking non-alcoholic fatty liver disease. EGCG’s potential to reverse inflammatory signaling in Subtype 1 holds considerable promise for chemopreventive applications aimed at reducing HCC incidence within at-risk populations.

Despite these promising findings, the scientists acknowledge the necessity for rigorous clinical validation of therapeutic candidates such as EGCG. Future efforts must prioritize the development of precision medicine approaches tailored to the molecular signature of individual CLD subtypes. For instance, interventions eliminating inflammation may benefit patients classified under Subtype 1, whereas targeted replenishment of metabolite deficiencies could be more effective in the aging-associated Subtype 2 cohort. Such stratified therapy paradigms could revolutionize HCC prevention by addressing the root molecular causes rather than merely managing symptoms or late-stage disease.

This research not only advances our understanding of liver carcinogenesis at the molecular level but also exemplifies the power of multi-omics analysis in biomarker discovery and therapeutic target identification. By integrating transcriptomic and metabolomic data, the team has provided a refined molecular taxonomy of CLD-related HCC risk that will guide future experimental and clinical endeavors. The ability to characterize the disease landscape with such precision marks a significant stride toward curbing the global burden of liver cancer.

Moreover, the study highlights the critical role of meticulous analysis of non-cancerous tissue adjacent to tumors, illuminating the microenvironmental factors that may facilitate malignant transformation. Recognizing that the pathophysiology of liver cancer extends beyond overt tumor cells to encompass surrounding liver tissue invites broader investigative and therapeutic perspectives, opening new windows for early intervention in at-risk individuals.

The collaborative effort behind this study reflects a comprehensive institutional synergy, involving Hiroshima University’s Graduate School of Biomedical and Health Sciences, Hiroshima Prefectural Hospital, and Hiroshima University Hospital. Supported by funding from the Japan Agency for Medical Research and Development as well as the Japan Society for the Promotion of Science, the research epitomizes the intersection of cutting-edge science and clinical relevance.

In summary, the findings from this multi-omics investigation underscore a paradigm shift in understanding non-viral hepatocellular carcinoma development. Distinct inflammatory and metabolic dysregulations characterize different CLD subtypes, each potentially amenable to targeted chemopreventive strategies such as EGCG supplementation. This nuanced insight holds the key to developing bespoke therapies that could substantially reduce liver cancer incidences, ultimately improving patient outcomes globally. As the burden of chronic liver diseases grows with aging populations and lifestyle factors, such scientific advances will be pivotal in transforming the landscape of liver cancer prevention and care.

Subject of Research: Molecular mechanisms of liver dysregulation leading to nonviral-related hepatocellular carcinoma development

Article Title: Multiomics Analysis of Liver Molecular Dysregulation Leading to Nonviral-Related Hepatocellular Carcinoma Development

News Publication Date: 21-Feb-2025

Web References:
https://pubs.acs.org/doi/10.1021/acs.jproteome.4c00729
https://regeo.org:8443/details.jsp?gseId=GSE77964

References:
Nakahara, H., Ono, A., et al., “Multiomics Analysis of Liver Molecular Dysregulation Leading to Nonviral-Related Hepatocellular Carcinoma Development,” Journal of Proteome Research, 2025.

Image Credits: Atsushi Ono, Hiroshima University Hospital

Keywords: Hepatocellular carcinoma, Internal medicine, Gastroenterology, Liver, Metabolic disorders